Ceritinib: A Targeted Therapy for ALK-Positive Non-Small Cell Lung Cancer
Harnessing precise molecular targeting for advanced non-small cell lung cancer treatment.
Get a Quote & SampleProduct Core Value
Ceritinib
Ceritinib is a crucial pharmaceutical chemical identified by CAS number 1032900-25-6, functioning as a potent ALK inhibitor. Its primary role is in the targeted treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC). This advanced therapy offers a precise approach to managing cancer by inhibiting the anaplastic lymphoma kinase (ALK) protein, which is overactive in certain cancer cells and drives their uncontrolled growth.
- Discover the efficacy of ceritinib as a targeted therapy for lung cancer, offering new hope to patients.
- Explore the advanced mechanism of action of ceritinib, an ALK inhibitor that halts cancer cell proliferation.
- Learn about the clinical application of ceritinib in treating ALK-positive metastatic NSCLC, as developed by Novartis.
- Understand the potential side effects and interactions associated with ceritinib therapy for informed treatment decisions.
Key Advantages
Precision Targeting
Ceritinib precisely targets the ALK gene fusion, offering a more effective treatment for specific patient populations within non-small cell lung cancer.
Enhanced Efficacy
As a potent ALK inhibitor, ceritinib demonstrates significant efficacy in patients whose tumors exhibit ALK rearrangements, often leading to improved outcomes compared to traditional chemotherapy.
Overcoming Resistance
Ceritinib has proven effective in patients who have developed resistance to earlier ALK inhibitors, providing a vital second-line treatment option.
Key Applications
ALK-Positive NSCLC Treatment
Ceritinib is specifically indicated for the treatment of patients with ALK-positive metastatic non-small cell lung cancer, a critical advancement in oncological care.
Targeted Cancer Therapy
It represents a leading example of targeted cancer therapy, focusing on specific molecular alterations within cancer cells to inhibit their growth and survival.
Pharmaceutical Research & Development
The development and ongoing research into ceritinib contribute significantly to the field of pharmaceutical R&D, particularly in personalized medicine approaches.
Oncology Drug Sourcing
Suppliers and researchers seeking high-quality pharmaceutical chemicals can find ceritinib for advanced cancer treatment research and formulation.